Contributions
Type: Publication Only
Background
No central registries for patients with mantle cell lymphoma (MCL) exist in Germany.
Aims
The objective of this analysis was to determine the number of patients with MCL diagnosed (with or without other diagnoses of cancer) and to characterize the types of treatment being utilized and care settings using sickness funds claim data.
Methods
This analysis evaluates data from 1,771,225 beneficiaries in 2012 from different statutory sick funds (SHI). MCL patients were identified by ICD-10 C83.1, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemotherapy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number (PZN) 9999092 and/or operating and procedure code (OPS) 854*.
Results
78 patients with a diagnosis of MCL (C83.1) could be identified (4/100.000). Overall gender ratio was 76.9% male and 23.1% female. Additional oncological diagnoses were found in 43.6% of patients. 20.7% had malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-80), 17.2% had malignant neoplasms of digestive organs (C15-26), 13.8% had melanoma (C43-44), 10.3% had neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-48), 8.6% had malignant neoplasms of urinary tract (C64-68) and malignant neoplasms of lip, oral cavity and pharynx (C00-14) (multiple diagnoses possible). The outpatient diagnosis rate was 64.1%, inpatient rate 15.4% and in- and outpatient 20.5%.
From a total of 78 patients 44 (56.4%) patients received chemotherapy (40 men [90.9%] and 4 women [9.1%]) in 2012. 25.0% of patients received both out- and in-patient treatment, 65.9% received out-patient treatment and 9.1% in-patient treatment. Identification of the administered substances was possible when ATC codes were reported. The most commonly used treatments were rituximab (34.7%), bendamustine (14.9%), cyclophosphamide (11.9%), vincristine (8.9%), doxorubicine (21.8%) and other treatments (21.8%) (multiple treatments possible).
Summary
Prevalence and gender ratio 3:1 was consistent with previously reported1,2. Most patients were diagnosed and treated as outpatients. Other oncological disorders are higher than in chronic lymphocytic leukemia³. About half of the patients were treated with chemotherapy within a year.
Keyword(s): Epidemiology, Mantle cell lymphoma, Prevalence
Session topic: Publication Only
Type: Publication Only
Background
No central registries for patients with mantle cell lymphoma (MCL) exist in Germany.
Aims
The objective of this analysis was to determine the number of patients with MCL diagnosed (with or without other diagnoses of cancer) and to characterize the types of treatment being utilized and care settings using sickness funds claim data.
Methods
This analysis evaluates data from 1,771,225 beneficiaries in 2012 from different statutory sick funds (SHI). MCL patients were identified by ICD-10 C83.1, oncological co-diagnoses by ICD-10 C00-79; D37-48 and chemotherapy by Anatomical Therapeutic Chemical (ATC) Code L01*, pharmacy number (PZN) 9999092 and/or operating and procedure code (OPS) 854*.
Results
78 patients with a diagnosis of MCL (C83.1) could be identified (4/100.000). Overall gender ratio was 76.9% male and 23.1% female. Additional oncological diagnoses were found in 43.6% of patients. 20.7% had malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-80), 17.2% had malignant neoplasms of digestive organs (C15-26), 13.8% had melanoma (C43-44), 10.3% had neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-48), 8.6% had malignant neoplasms of urinary tract (C64-68) and malignant neoplasms of lip, oral cavity and pharynx (C00-14) (multiple diagnoses possible). The outpatient diagnosis rate was 64.1%, inpatient rate 15.4% and in- and outpatient 20.5%.
From a total of 78 patients 44 (56.4%) patients received chemotherapy (40 men [90.9%] and 4 women [9.1%]) in 2012. 25.0% of patients received both out- and in-patient treatment, 65.9% received out-patient treatment and 9.1% in-patient treatment. Identification of the administered substances was possible when ATC codes were reported. The most commonly used treatments were rituximab (34.7%), bendamustine (14.9%), cyclophosphamide (11.9%), vincristine (8.9%), doxorubicine (21.8%) and other treatments (21.8%) (multiple treatments possible).
Summary
Prevalence and gender ratio 3:1 was consistent with previously reported1,2. Most patients were diagnosed and treated as outpatients. Other oncological disorders are higher than in chronic lymphocytic leukemia³. About half of the patients were treated with chemotherapy within a year.
Keyword(s): Epidemiology, Mantle cell lymphoma, Prevalence
Session topic: Publication Only